Wire · opportunities
iPSC Cardiomyocytes Reach the Beating Heart: What This Trial Design Tells Sponsors ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 August 2026 · Fusion42 review
A 2026 randomized trial delivered allogeneic iPSC-derived cardiomyocytes via intramyocardial injection for advanced ischemic heart failure, highlighting operational protocol choices around immune suppression, delivery complexity, and regulatory manufacturing comparability that will shape future cardiac cell therapy development.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Cardiac cell therapy founders must treat immune suppression and manufacturing comparability as direct constraints, not afterthoughts, and factor clinical site capabilities into trial design now. Expect new FDA electrophysiology monitoring demands that will reshape your development plan.
◆ Coverage
1 source · 20 Aug 2026
◆ Related on Wire
◆ Topics